Amgen’s Rise
- Share via
Amgen’s stock has climbed more than 100% in the last year. The world’s biggest biotech company is poised to see bigger gains as new research shows its drug NESP is as effective as its blockbuster Epogen drug. Weekly closes and latest:
Monday: $81.44, up $3.56
Source: Bridge News
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
